With the rapid development of immunotherapy, programmed cell death 1 (PD1) and its ligand (PD-L1) checkpoint inhibitors have become alternative options for advanced patients, enhancing the anticancer immune response by relaunching T-cell–mediated tumor cell death programs through blocking the interaction between PD1 and PD-L1 (Reck, 2018; Dhillon and Syed, 2019). Here, PDCD1 is linked to neoplasm.